MLAB Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

101.000

Open

99.340

VWAP

99.06

Vol

109.84K

Mkt Cap

545.58M

Low

97.430

Amount

10.88M

EV/EBITDA(TTM)

16.24

Total Shares

5.52M

EV

685.99M

EV/OCF(TTM)

16.52

P/S(TTM)

2.22

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.

Show More

Events Timeline

(ET)

2026-03-09

16:40:00

Mesa Labs Appoints Siddhartha Kadia as New CEO

2026-02-03 (ET)

2026-02-03

08:10:00

Mesa Reports Q3 Revenue of $65.126M, Beating Consensus

2025-11-06 (ET)

2025-11-06

16:44:20

Mesa Labs announces Q2 earnings per share of 45 cents, down from 63 cents a year ago.

2025-09-22 (ET)

2025-09-22

04:55:00

S&P Dow Jones Indices Reveals Quarterly Rebalancing Update

2025-09-05 (ET)

2025-09-05

17:29:12

S&P Dow Jones Indices Reveals Quarterly Rebalancing Update

2025-08-05 (ET)

2025-08-05

08:15:45

Mesa Labs reports Q1 EPS 85c vs 62c last year

News

NASDAQ.COM

04-06NASDAQ.COM

Citigroup, Maximus, Lindsay Declare Quarterly Dividends

seekingalpha

04-03seekingalpha

Mesa Laboratories Declares Quarterly Dividend of $0.16

Newsfilter

04-02Newsfilter

Mesa Laboratories Declares Quarterly Dividend

NASDAQ.COM

03-17NASDAQ.COM

MLAB Stock 52-Week High and Low Analysis

Benzinga

U.S. Stocks Mixed in Morning Trading

seekingalpha

03-09seekingalpha

Mesa Laboratories CEO Transition and Earnings Beat Expectations

2 Analyst Rating

Wall Street analysts forecast MLAB stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

83.00

Averages

99.00

High

115.00

Current: 0.000

Low

83.00

Averages

99.00

High

115.00

Wells Fargo

Equal Weight

maintain

$83 -> $94

AI Analysis

2026-02-04

Reason

Wells Fargo

Price Target

$83 -> $94

AI Analysis

2026-02-04

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Mesa Labs to $94 from $83 and keeps an Equal Weight rating on the shares. The firm notes the company posted a solid beat on Q3 revenue and adjusted EBITDA, with strong margin expansion despite foreign-exchange headwinds. With numbers moving up, leverage down and management taking more shareholder-friendly steps, there's more room for valuation to re-rate, in Wells' view.

Wells Fargo

Equal Weight

maintain

$75 -> $83

2025-12-15

Reason

Wells Fargo

Price Target

$75 -> $83

2025-12-15

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Mesa Labs to $83 from $75 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MLAB

Unlock Now

Valuation Metrics

The current forward P/E ratio for Mesa Laboratories Inc (MLAB.O) is 35.21, compared to its 5-year average forward P/E of 31.14. For a more detailed relative valuation and DCF analysis to assess Mesa Laboratories Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

31.14

Current PE

35.21

Overvalued PE

46.90

Undervalued PE

15.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

18.19

Current EV/EBITDA

10.85

Overvalued EV/EBITDA

24.64

Undervalued EV/EBITDA

11.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.81

Current PS

2.08

Overvalued PS

5.85

Undervalued PS

1.77

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

one day increase of at least 2 percent

Intellectia · 453 candidates

Region: USPrice Change Pct: >= $2.00

Ticker

Name

Market Cap$

Actelis Networks Inc

3.29M

Acurx Pharmaceuticals Inc

7.39M

Golden Sun Technology Group Ltd

5.08M

Commercial Vehicle Group Inc

59.50M

KALA BIO Inc

267.84M

Sos Ltd

12.07M

under a half a billion I meant

Intellectia · 427 candidates

Market Cap: <= 500.00MPrice Change Pct: $-5.00 - $5.00Moving Average Relationship: PriceCrossAboveMA5, PriceCrossAboveMA20

Ticker

Name

Market Cap$

BlackRock TCP Capital Corp

498.02M

Ennis Inc

494.48M

Reservoir Media Inc

492.57M

Priority Technology Holdings Inc

490.41M

First Business Financial Services Inc

489.38M

Marcus Corp

488.66M

Whales Holding MLAB

Ranger Investment Management, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Mesa Laboratories Inc (MLAB) stock price today?

The current price of MLAB is 98.75 USD — it has decreased -0.59

What is Mesa Laboratories Inc (MLAB)'s business?

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.

What is the price predicton of MLAB Stock?

Wall Street analysts forecast MLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLAB is99.00 USD with a low forecast of 83.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Mesa Laboratories Inc (MLAB)'s revenue for the last quarter?

Mesa Laboratories Inc revenue for the last quarter amounts to 65.13M USD, increased 3.64

What is Mesa Laboratories Inc (MLAB)'s earnings per share (EPS) for the last quarter?

Mesa Laboratories Inc. EPS for the last quarter amounts to 0.65 USD, decreased -309.68

How many employees does Mesa Laboratories Inc (MLAB). have?

Mesa Laboratories Inc (MLAB) has 730 emplpoyees as of April 17 2026.

What is Mesa Laboratories Inc (MLAB) market cap?

Today MLAB has the market capitalization of 545.58M USD.